

Dr. Lal PathLabs Limited records revenue of Rs 452.4 Cr in Q3 FY 2020-21

New Delhi, India, January 29, 2021 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2020

Consolidated Performance Highlights: Q3 FY 2020-21 vs Q3 FY 2019-20

Revenue: Rs 452.4 Cr, a growth of 38.0%
Normalised EBITDA at Rs 144.6 Cr with margin at 32.0%
PBT at Rs 128.9 Cr with margin at 28.5%, and
PAT Rs 95.9 Cr with margin at 21.2%

- Operating Revenue increased by 38.0% in Q3 FY21 to Rs. 452.4 Cr vs Rs 327.9 Cr in Q3 FY20
- Covid and Allied contributed 21.6% to Revenue in Q3 FY21 with 5.27 lac RTPCR tests
- Normalised EBITDA (after adjustment for stock based compensation & CSR cost) for Q3 FY21 is at Rs. 144.6 Cr Vs Rs 88.9 Cr in the same quarter last year
- PBT is at Rs 128.9 Cr in Q3 FY21 vs Rs 73.4 Cr. in Q3 last year
- Profit after Tax in Q3 FY21 at Rs. 95.9 Cr as compared to Rs 54.9 Cr in Q3 last year
- Interim Dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board

Financial Overview (Consolidated) in Rs Cr

Particulars	Q3 FY21	Q3 FY20	Gr %	YTD Dec'20	YTD Dec'19	Gr %
Revenue	452.4	327.9	38.0%	1150.3	1028.7	11.8%
Expenditure	313.6	245.6		836.0	742.4	
EBITDA	138.8	82.3	68.7%	314.3	286.3	9.8%
Adj for Stock Based Compensation & CSR cost	5.8	6.6		18.8	15.1	
Normalised EBITDA	144.6	88.9	62.7%	333.1	301.4	10.5%
Normalised Margins	32.0%	27.1%		29.0%	29.3%	
Other income	13.5	13.8		37.8	43.0	
PBT	128.9	73.4	75.6%	283.6	265.1	7.0%
Margins	28.5%	22.4%		24.7%	25.8%	
PAT	95.9	54.9	74.7%	211.4	195.0	8.4%
Margins	21.2%	16.7%		18.4%	19.0%	
EPS (Basic)	11.44	6.56	74.4%	25.23	23.48	7.4%
EPS (Diluted)	11.41	6.55	74.2%	25.16	23.42	7.4%



About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2020 the company has 216 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,095 Patient Service Centers (PSCs) and 6,995 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Prakash Goel
Chief Financial Officer
Dr. Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Mittali Bharti
Adfactors PR

+91 9871154558
mittali.bharti@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.